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Abstract (236 words) 
In order to prevent re-replication of genomic segments, the eukaryotic cell 
cycle is divided into two non-overlapping phases. During late mitosis and G1, 
replication origins are ‘licensed’ by loading MCM2-7 double hexamers; during 
S phase, licensed replication origins activate and act as initiation points for the 
bidirectional forks responsible for DNA replication. Replication forks can stall 
irreversibly, and if each of two converging forks both stall with no licensed 
origin between them - a ‘double fork stall’ (DFS) - replication cannot be 
completed by conventional means. To compensate, more origins are licensed 
than are normally used with most (typically >70%) remaining dormant. We 
previously showed how the distribution of replication origins in yeasts allows 
complete genome replication in the presence of irreversible fork stalling. This 
analysis predicts that DFSs are rare in yeasts but highly likely in large 
mammalian genomes. Here we show that ultrafine anaphase bridges and G1-
specific 53BP1 nuclear bodies provide a mechanism for resolving 
unreplicated DNA at DFSs in human cells. When origin number is 
experimentally altered, the number of these structures closely coincides with 
predictions of DFSs. 53BP1 is preferentially bound to larger replicons, where 
the probability of DFSs is higher. Loss of 53BP1 causes hypersensitivity to 
replication inhibition when replication origins are removed. These results 
provide a striking convergence of experimental and theoretical evidence that 
unreplicated DNA can pass through mitosis for resolution in the next cell 
cycle.  
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Significance Statement (118 words) 
We provide evidence that in organisms with gigabase sized genomes, 
such as humans, one or more stretches of DNA typically remain unreplicated 
when cells enter mitosis and are segregated to daughter cells via structures 
called ultrafine anaphase bridges. These stretches of DNA are recognised in 
the following G1-phase by 53BP1 for final resolution in S-phase. We show 
that the abundance of these structures match our theoretical predictions for 
the amount of unreplicated DNA when the number of replication origins is 
artificially increased or decreased. We show that 53BP1 preferentially binds to 
chromosomal regions with low numbers of replication origins. This work 
provides a new perspective about how genome stability is maintained in 
proliferating cells.  
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Introduction 
During the eukaryotic cell cycle, the genome should be precisely 
duplicated with no sections left unreplicated and no sections replicated more 
than once. In order to prevent re-replication, the process is divided into two 
non-overlapping phases: during late mitosis and G1, replication origins are 
‘licensed’ for subsequent use by loading MCM2-7 double hexamers; during S 
phase, DNA-bound MCM2-7 is activated to form processive CMG (CDC45-
MCM-GINS) helicases which drive replication fork progression. The 
prohibition of new origin licensing during S phase or G2, ensures that re-
replication of DNA cannot occur. However, the inability of cells to license new 
origins after S phase has started makes it harder to ensure that all the 
genome is fully replicated. Replication forks can stall irreversibly when they 
encounter problems such as DNA damage or tightly bound protein-DNA 
complexes.  
When replication initiation occurs at a licensed replication origin the 
Mcm2-7 double hexamer is split apart to form a pair of bidirectional CMG 
helicases (1-3). This means that if one fork irreversibly stalls, all of the DNA 
can still be replicated because the other converging fork can compensate by 
replicating all the DNA up to the stalled fork. However, if each of two 
converging forks both stall and there is no licensed origin between them - a 
‘double fork stall’ (DFS) - there is no easy way to replicate the intervening 
DNA (4). To compensate for these replication problems, more origins are 
licensed than are normally used, with most (typically >70%) remaining 
dormant but capable of becoming active if needed (5-9). We previously used 
mathematical analysis to show how the distribution of replication origins in 
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yeasts can be explained by the need for complete genome replication in the 
presence of irreversible fork stalling (4). Our theory predicts that organisms 
with significantly larger genomes than yeast, such as those of mammals, will 
experience a much greater probability of replication failure genome-wide.  
In this work, we provide evidence for a post-replicative mechanism that 
allows the resolution of these unreplicated segments of DNA that involves 
separation of template DNA strands during mitosis by the creation of ultrafine 
anaphase bridges (UFBs), and their recognition in the subsequent G1 phase 
by the DNA repair protein 53BP1. We show that 53BP1 nuclear bodies 
correlate with the expected number of DFSs, both when the number of 
replication origins is reduced and when they are increased. We also show that 
53BP1 preferentially associates with DNA in larger replicons as predicted by 
the theoretical analysis. This experimental work strongly supports the 
theoretical analysis of DFSs in organisms of differing genome size that we 
present in an accompanying paper (10). 
 
Results 
Refinements in technology have led to a convergence of origin mapping 
data in mammalian tissue culture cells (11-13). Fig 1A shows the spacing 
between ~90,000 replication origins in HeLa cells derived from the data of 
Picard et al (13). The average inter-origin distance is ~31 kb, consistent with 
initiation events being ~100 kb apart (11, 14, 15) and ~30% of origins being 
stochastically activated in any given S phase (6-9, 16, 17). Compared to 
yeast, human cells have unevenly distributed origins with an unexpectedly 
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high number of very large replicons (10). Using a mathematical approach that 
we have previously derived and validated (4) we estimate that one or two 
DFSs are expected to occur in every HeLa cell S phase (Fig. 1B). Similar 
numbers were obtained when we performed computational analyses based 
on the origin mapping data from both HeLa and primary IMR90 cells (Fig. 1B). 
The predicted number of DFSs increases when replication origins are 
removed and increases when they are added (Fig. 1B). Theoretical analysis 
can explain the distribution of origins in human cells if they possess a post-
replicative mechanism capable of resolving DFSs so long as they remain 
small in number (10). 
Since a DFS will create a large segment of unreplicated DNA, our 
analysis suggests that human and other vertebrates with larger genomes than 
yeasts have evolved mechanisms to deal with them. Unreplicated or damaged 
DNA might be topologically unhooked and then segregated during mitosis for 
repair in the next cell cycle (18, 19) (Fig. 1C). Chromatid condensation 
or segregation during mitosis could provide a processive unwinding activity to 
separate unreplicated DNA, leaving single-stranded gaps that could then be 
partially filled in during mitosis (20) or the following cell cycle. Because this 
mechanism depends on the resolution and segregation of topologically 
intertwined strands, it might be able to deal with only a small number of DFSs, 
as our theory predicts (10).  
Previous studies have suggested that 53BP1 might be involved in the 
recognition of these aberrant structures in the next cell cycle. 53BP1 forms 
‘nuclear bodies’ in G1 phase that are symmetrically distributed between sister 
cells and which could result from unreplicated DNA in a parent cell being 
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inherited by its daughters (18, 21). Consistent with this idea, the number of 
53BP1 nuclear bodies increases in cells treated with replication inhibitors (22-
24) (Fig. 1D and S1A-B) suggesting that 53BP1 can recognise structures 
resulting from defective DNA replication. As our theory predicts (10), 53BP1 
nuclear bodies in normal G1-phase cells follow a Poisson distribution 
(suggesting that they are independent stochastic events) with a mean close to 
the predicted number of DFSs (Fig. 1E and S1C-D). The number remains 
stable during G1, but declines during S-phase, supporting the idea that they 
are resolved in a replication-dependent manner (Fig. 1F and S1E).  
In order to provide evidence for a link between DFSs and 53BP1 nuclear 
bodies, we depleted replication origins using RNAi against the origin licensing 
machinery (6) (Fig. 2A and S2A). We used a 3D flow cytometry protocol 
measuring DNA content, EdU incorporation and chromatin-bound Mcm2 to 
determine the amount of chromatin-bound MCM2-7 in cells entering S phase 
(Fig. 2B). Depletion of MCM5 by RNAi reduced the amount of DNA-bound 
MCM2 at S phase entry (Fig. 2C). Similar results were obtained with RNAi 
against the licensing factor Cdt1 (Fig. S2A-B). In both cases, EdU 
incorporation was not affected (Fig. S2C). Importantly, decreasing the number 
of licensed origins increased the number of 53BP1 nuclear bodies (Fig. 2D 
and S2D-E).  
We then used a human bronchial epithelial cell line overexpressing Cdc6 
to increase DNA-bound MCM2-7 (Fig. 2E). The number of 53BP1 nuclear 
bodies in these hyper-licensed cells was reduced 30% compared to non-
induced controls (Fig. 2F and S3A-B). Fig. 3A shows that there is was 
excellent agreement between our theoretical predictions and the experimental 
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data from cells with reduced or increased numbers of licensed origins (Figs 
2D, 2F, S1D and S2B). This provides strong support for the idea that failures 
of DNA replication caused by spontaneous DFSs cause the appearance of 
53BP1 nuclear bodies in the subsequent G1.  
Although DFSs can occur at any region of the genome, theoretical 
analysis predicts that they are more likely in larger replicons rather than 
smaller ones (4). To test this, we performed chromatin immunoprecipitation 
with anti-53BP1 antibodies and sequenced the precipitated DNA (Fig. S4). 
53BP1 can bind to DNA throughout the nucleus, not only in ‘nuclear bodies’ 
(Fig. S5A-B); consistent with this, the genomic coverage from 53BP1 and IgG 
precipitations were comparable (Fig. S5C). However, the 53BP1/IgG binding 
ratio showed very significant correlation between the replicon size and 53BP1 
association (Fig. 3B and S4D). There was also a weak correlation between 
53BP1 binding, chromosome fragile sites and late replicating DNA (Fig. S5D-
E). We then identified 1 kb regions of the genome with a high 53BP1/IgG ratio 
(p-value < 10-3); replicons were defined as 53BP1+ when they contained one 
or more 53BP1-enriched regions, and 53BP1- otherwise. 53BP1+ replicons 
were on average ~3 times larger than 53BP1- replicons (Fig. 3C-D, and S5F). 
Taken together, these analyses show that 53BP1 is more likely to bind to 
DNA in large replicons, as predicted if 53BP1 recognises DNA structures 
resulting from DFSs.  
In the absence of the replicative CMG helicase to unwind DNA between 
stalled forks, force from the mitotic spindle or chromosome condensation 
could work with the BLM helicase to separate DNA in Ultrafine Anaphase 
Bridges (UFBs) (20, 25-27) (Fig. 1C). In untreated HeLa cells, the numbers of 
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UFBs closely matched the numbers of 53BP1 nuclear bodies. Further, the 
number of UFBs increased in line with 53BP1 nuclear bodies when MCM2-7 
was partially depleted. This is consistent with the idea that UFBs represent a 
major mechanism by which unreplicated DNA generated by DFSs is passed 
to daughter cells to become 53BP1 nuclear bodies (Fig. 4A-B). If partially 
replicated DNA is segregated during mitosis as outlined in Fig. 1C, ssDNA will 
be exposed, thereby providing a template for complementary strand synthesis 
which could result in much of the single-stranded gap being filled in.  
In order to investigate the nature of 53BP1 nuclear bodies, we 
investigated the co-localisation of 53BP1 nuclear bodies with the ssDNA 
binding protein RPA (Replication Protein A). In untreated cells, ~7% 53BP1 
nuclear bodies were associated with measurable levels of RPA (Fig. 4C) (18), 
but partial depletion of MCM2-7 caused a large increase in colocalisation. 
This might reflect the larger distance between stalled forks, and hence longer 
stretches of unreplicated DNA, caused by a reduction in origin number. 
Since we predict that DFSs occur with high frequency, 53BP1 must be 
performing a function in binding to the products of DFSs in G1 phase. 53BP1 
is known to protect broken DNA from undergoing homologous recombination 
(28), and it may perform this function at DFSs, which might allow the 
structures to be resolved by an alternative pathway in S phase. To explore 
this idea further, we examined a possible synthetic interaction between loss of 
53BP1 and an increase in DFSs created by partial knockdown of MCM2-7. 
RNAi transfected cells were treated with different doses of hydroxyurea (HU) 
before a colony assay was performed. Cells partially depleted for MCM2-7 
were hypersensitive to HU, due to their inability to utilise dormant replication 
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origins (6-8). 53BP1-depleted cells showed a similar sensitivity to control 
cells. However cells depleted of 53BP1 showed a highly synergistic sensitivity 
to HU when combined with partial knockdown of MCM5 (Fig. 4 E-F and S5G). 
This shows that although 53BP1 is not essential, it works together with 
dormant origins to protect cells from the consequences of replication fork 
failure. 
 
Discussion 
In this work we present evidence that in unperturbed cell cycles of human 
cells, unreplicated DNA is frequently present at the end of G2 and is 
segregated during mitosis for resolution during the following cell cycle. Our 
theoretical analysis suggests that in organisms such as humans with 
gigabase-sized genomes, DFSs will occur that create stretches of 
unreplicated DNA that must be dealt with by a post-replicative mechanism (4, 
10). Because of their symmetrical distribution and their induction by replicative 
stresses, we have examined whether 53BP1 nuclear bodies in G1 cells mark 
the products of unreplicated DNA being segregated to daughter cells. We 
show that when replication origins are deleted or added there is a strong 
correlation between the number of 53BP1 nuclear bodies and our theoretical 
predictions of DFSs as presented in an accompanying paper (10).  
We show that 53BP1 is preferentially bound to DNA in larger replicons, 
where DFSs are more likely to occur. In addition, 53BP1 synergises with 
dormant origins to protect genome integrity in the presence of replicative 
stress, as evidenced by its hypersensitivity to HU when the number of 
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dormant origins was reduced. Ultrafine anaphase bridges represent a 
potential intermediate that could allow unreplicated DNA to be segregated 
during mitosis, and we show that the number of these structures is similar in 
number to predicted DFSs and increase in line with our predictions when 
origin number is reduced. The role of ultrafine anaphase bridges is particularly 
attractive as it can provide an effectively processive unwinding activity to 
replace the CMG activity lacking at a DFS.  
Recent work has provided evidence that when cells are treated with DNA 
damaging agents or replication inhibitors, DNA can be topologically unhooked 
during mitosis for subsequent repair (18-20). This provides a good 
mechanism to deal with the unreplicated DNA that results from spontaneous 
DFSs. We observed that a proportion of the 53BP1 nuclear bodies in G1 
phase colocalised with RPA, suggesting that they contained significant 
quantities of ssDNA. The proportion of 53BP1 nuclear bodies colocalising with 
RPA increased when the number of replication origins was experimentally 
reduced. Once ssDNA is exposed it is reasonable to imagine the DNA 
polymerases will perform complementary strand synthesis to substantially fill 
in the gaps. A recent paper has provided evidence that such post-replicative 
DNA synthesis can occur during metaphase (20). We speculate that gaps 
between spontaneous DFSs are substantially filled in in this way, leaving 
some DNA abnormalities that are recognised by 53BP1 in G1 and which are 
only completely resolved during the next S phase. Our study therefore 
provides strong experimental and theoretical evidence that structures 
resulting from replication failure can pass through mitosis for resolution in the 
next cell cycle.  
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Materials and Methods  
Cell Culture 
HeLa cells were obtained from the American Type Culture Collection 
(ATCC) and used at a population doubling level lower than 30, and 
maintained in Dulbecco’s modified Eagle’s medium (DMEM; #41966, 
Invitrogen), supplemented with 10% FBS (#10270106, Invitrogen) and 
antibiotics at 37˚C in 5% CO2. HBEC-Cdc6-Tet-On (Human Bronchial 
Epithelial Cells) were grown in keratinocyte serum-free medium (#17005-075, 
Invitrogen) supplemented with 50 µg/ml Bovine Pituitary Extract and 5 ng/ml 
hEGF (#17005-075, Invitrogen). Cells were developed as described in (29). 
Briefly, immortalized HBECs were infected with PLVX-Tet-On with blasticidin 
resistance (3 µg/ml) and PLVX-TRE-Cdc6 with zeocin resistance (12.5 µg/ml). 
Clones with robust doxycycline-dependent induction (5 µg/ml) were selected.  
 
RNAi and Transfections 
siRNA duplexes were obtained from Thermo Fisher Scientific, and the 
sequences were as follows:  
CONTROL: 5’-UAGCGACUAAACACAUCAA -3’ 
MCM5: 5’-GGAUCUGGCCAGCUUUGAU -3’ 
CDT1: SMARTPool M-003248-02 
53BP1: 5’- GAAGGACGGAGUACUAAUA-3’ 
Transfection was performed with Lipofectamine RNAiMAX (Invitrogen). 50 
nM siRNA was mixed with the Lipofectamine in Opti-MEM medium 
(Invitrogen). The mixture was added to 50-60% confluent cells that contained 
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DMEM (Invitrogen) without antibiotics. Cells were subjected to different times 
of transfection to obtain different efficiencies. 
 
Immunoblotting and Antibodies 
Immunoblotting was performed as previously described (8). Western 
blotting were performed according to standard procedures. The antibodies 
used were: anti-Mcm5 (Santa Cruz, sc-136366), anti-Cdt1 (abCam, 
ab183478), Tubulin (Sigma-Aldrich, T6199), 53BP1 (Bethyl, A300-272A), 
Lamin B (abCam, 16048), GAPDH (abCam, ab9484), Cdc6 (Millipore, 05-
550). 
 
Immunofluorescence 
Cells were seeded in 6-well plates containing glass coverslips. At the 
required times for each experiment, they were fixed with 4% formaldehyde, 
permeabilised with 0.1% Triton X-100 in TBS and blocked with 0.5% Fish 
Gelatin (Sigma, G-7765) for one hour. Cells were then incubated with the 
relevant antibodies overnight at 4ºC and washed with 0.1% TBS-Tween 
before incubation with Alexa secondary antibodies (Invitrogen). Cells were 
incubated with DAPI (Sigma, D9542) and mounted using Vectashield 
mounting medium (Vector Laboratories, H-1000). The antibodies used were: 
53BP1 (Novus, NB-100-904), Cyclin A (abCam, ab16726), BLM (Santa Cruz, 
sc-7790) and RPA (abCam, ab2175) 
 
Image acquisition and analysis 
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Microscopy images were acquired using an Olympus IX70 deltavision 
deconvolution microscope. An Olympus 63x oil immersion objective was 
used, and images were captured using a CCD camera. Data from microscopy 
experiments was analysed using Volocity 3D analysis software (Perkin 
Elmer). The nucleus was outlined as the ROI, and lower intensity threshold 
was set to a number that indicated the intra-nuclear background. This gave 
readout of the number of nuclear bodies and their intensities.  
 
3D Flow Cytometry 
Cells were treated with 40 µM EdU (Invitrogen) for 30 min prior to 
trypsinization and collection. Cells were pre-extracted with CSK buffer (10mM 
HEPES pH 7.4, 300 mM Sucrose, 100 mM NaCl, 3 mM MgCl2, 0.5% Triton-X-
100) for 10 min on ice and then fixed in 2% formaldehyde for 15 min. For 
MCM2 labelling, cells were permeabilised in ice-cold 70% ethanol for 10 min 
and incubated for 1 hr with anti-BM28 primary antibody (1:500). After staining 
with AlexaFluor 488-labelled secondary antibody (Invitrogen) cells were 
washed and Click-it EdU reaction was performed for 30 min. Finally, cells 
were treated with PI solution (50 µg/ml PI, 50 µg/ml RNaseA, 0.1% Triton-X-
100) and transferred to FACS tubes for analysis. Samples were acquired 
using a BD FACSCanto and results analysed using FlowJo software. 
 
ChIP-Sequencing 
Cells were crosslinked for 30 min using 1.5 mM ethylene glycol bis 
(succinimidyl succinate) followed by 10 min with 1% formaldehyde. Reactions 
were stopped with 2 M glycine and cells were resuspended in CSK buffer for 
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10 min. Cells were treated with 5 µl Micrococcal Nuclease (2000 U/µl) for 10 
min at 37˚C, neutralized with 2xRIPA (100 mM Tris-HCl pH 7.4, 300 mM 
NaCl, 2% IGE-Pal CA-630, 0.5% Na deoxycholate, 1 mM EDTA) and 
incubated on ice for 10 min. Samples were then pre-cleared with Protein A 
Dynabeads for 1 hr at 4˚C and then incubated with 7 µg anti-53BP1 antibody 
(Bethyl, A300-272A) overnight at 4˚C with rotation. DNA was eluted (1% SDS, 
0.1M NaHCO3, 0.1% Tween-20) and used for library preparation using the 
NEBNext ChIP-seq kit and sequenced on an Illumina HiSeq 2500 by the 
Edinburgh Genomics. The raw sequence data was assessed, aligned and 
combined using R version 3.2.2, Rsubread version 1.20.2 and samtools 
version 1.2. Aligned reads were analysed using scripts based on R version 
3.2.2 and Rsamtools 1.22. The quality assessment and a detailed description 
of the analysis pipeline are available in Supplementary text. Files containing 
the aligned reads are available at the European Nucleotide Archive 
(Accession number: PRJEB12222) and at https://goo.gl/OwBMWa, and the R 
script used for the analysis is available as a supplementary file.  
 
Mathematical and computational analysis  
The mean number of DFS was computed with the formula: 
log 2 𝑁𝑔𝑁𝑠 −   log 1 + log 2 𝑁𝑖𝑁𝑠𝐾𝑖=1   
 
where 𝑁!  indicates the genome size, 𝑁!  indicates the median stalling 
distance, and the 𝑁!(𝑖 = 1. . 𝑘)  indicate the length of the 𝐾  replicons. RO 
depletion and augmentation experiments were performed by randomly 
removing or increasing the number of RO. More details on the mathematical 
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model used are described in (4) and (MAM, LA, AM, JJB, TJN, in preparation) 
and an extended summary of the approach used is available in the 
Supplementary text. 
 
Clonogenic Assay 
Cells were transfected in 10 cm dishes and replated into 6-well dishes 
before treatment. Hydroxyurea was added to cells for 48 hr before medium 
was replaced with fresh growth medium. After 10 days, cells were washed, 
fixed and stained with Crystal Violet. The number of colonies >1 mm were 
recorded. For each genotype, cell viability of untreated cells was defined as 
100%. 
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Figure Legends 
 
Figure 1. Potential mechanism for resolution of DFSs 
A) Distribution of replicon sizes in HeLa cells, calculated from (13). B) Mean 
number of DFSs predicted using a mathematical model (4), and a 
computational model using origin data from HeLa and IMR90 (13) when 
origins are added or depleted randomly. C) Model for segregation of 
unreplicated DNA to daughter cells for resolution in the next cell cycle. D) 
53BP1 nuclear bodies in untreated and aphidicolin-treated cells. E) Frequency 
of 53BP1 nuclear bodies in G1-cells (n=100; three independent experiments). 
χ2 test for a fitted Poisson, p-value=0.771. F) 53BP1 nuclear bodies in G1 at 
different times after mitotic shake-off. χ2 test, p-value = 0.924. G) 53BP1 
nuclear bodies at different stages of S-phase. χ2 test, p-value = 4.998x10-4.  
 
Figure 2. Changing origin number affects 53BP1 nuclear bodies 
A) Immunoblot of total and chromatin-bound MCM5 in HeLa cells after MCM5 
RNAi. B) 3D FACS of HeLa cells labelled with EdU (left) and MCM2 (right). C) 
FACS of MCM2 levels at early S-phase in HeLa cells ±MCM5 RNAi. D) 
Number of 53BP1 nuclear bodies in G1-cells (y axis) after MCM5 knockdown 
quantified by 3-D FACS (x axis). Each dot represents the mean of 100 cells. 
E, F) Cdc6-inducible HBEC cells. Immunoblot of CDC6 and tubulin in whole 
cell lysates (E, top) and MCM5 and lamin B in chromatin samples (E, bottom). 
Frequency of 53BP1 nuclear bodies in HBEC cells (F) (n=100; three 
independent experiments). χ2 test for fitted Poisson, p-values > 0.87). The two 
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conditions are significantly different (Wilcoxon rank sum test, p-value = 
2.843x10-6) 
 
Figure 3. Concordance of theoretical and experimental results 
A) Compilation of the predicted number of DFSs using the mathematical 
model and the computer simulation (from Fig 1B) and the mean number of 
53BP1 nuclear bodies in vivo (from Fig 2D, 2F and S3D). B) Plot of the 
average 53BP1/IgG signal ratio per kilobase against replicon size. A strong 
and significant correlation is observed (Spearman ρ = 0.91, p-value < 10-15) 
C) Distribution of the size of 53BP1+ and 53BP1- replicons (t test, p-value < 
10-15). D) Frequency distribution of 53BP1+ and 53BP1- across different 
replicon sizes (χ2 test, p-value < 10-15). 
 
Figure 4. Other features of 53BP1 and Ultrafine Anaphase Bridges 
A) UFBs stained for BLM (red) and DAPI (blue). B) Number of UFBs plus or 
minus maximal MCM5 RNAi ± SEM (B). C) Frequency distribution of UFBs 
(n=100 cells; 4 independent experiments). χ2 test for a Poisson, p-values > 
0.85. A significant difference was observed (Wilcoxon rank sum test, p-value 
= 5.095x10-3) D) Colocalisation of 53BP1 and RPA. E) Colocalisation of 
53BP1 nuclear bodies with RPA plus or minus maximal MCM5 RNAi (mean of 
three independent experiments ± SEM). F, G) HeLa cells were treated 
±MCM5 RNAi and/or 53BP1 RNAi. Immunoblots of total cell lysate (F). 
Clonogenic assay after treatment with increasing HU (mean of 3 experiments 
± SEM) (G). 
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cycle 
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Replication origin (RO) dataset 
Genomic regions of HeLa associated with replication origins were 
obtained from the OriSeq project (13) using the h19 human genome. Each 
genomic region was associated with a single point on the genome, which was 
obtained by taking the middle points of the genomic region under 
consideration. The replication origin positions allowed us to divide each 
chromosome into a set of replicons, defined as area on a chromosome 
delimited on both side by replication origins. The largest replicon of each 
chromosome was removed from the analysis since these replicons 
correspond to the centromeric areas, which are difficult to study using 
sequencing experiments. When the replication origin positions were used to 
compute the probability of double fork stalls (DFSs), the genome size was 
adjusted accordingly. These data were used in all the circumstances that 
required the position of ROs. 
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Mathematical model and computational simulations 
The details of the mathematical model used with an extensive analysis of 
its theoretical consequences can be found in (MAM, LA, AM, JJB, TJN, in 
preparation) and only a limited description will be presented here. In (4) we 
derived a simple model of DFS, using 2 assumptions: that all the licensed 
ROs can be activated as necessary (therefore any time constraint is excluded, 
a condition likely to be true for somatic human cells), and that there is a 
constant small probability per nucleotide for each individual replication fork to 
irreversibly stall. In the same article, we showed that if all the replicons are 
significantly smaller than the median stalling distance and with a distribution, 
characterized by a limited dispersion (conditions compatible with 
experimentally-derived replicon size distribution in yeasts), the probability of at 
least one double fork stall in a given cell cycle is  
 
P(zero DFS) ≈ 1− log 2 !2 𝑁!𝑁!𝑁!! 1+ 𝑅!                                                            (Eq. 1)  
 
Where 𝑁! is the average replicon size, 𝑁! is the size of the genome, 𝑁! 
is the median stalling distance and 𝑅  is the ratio of the standard 
deviation to the mean of the replicon size distribution. 
 
Since in human cell lines a very large variation can be observed in 
replicon size and few replicons are as large as half of the median stalling 
distance, the above approximation is inappropriate. Hence, we lifted this 
approximation and used an exact approach (MAM, LA, AM, JJB, TJN, in 
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preparation). Under these new conditions, in a given genome with K replicons 𝑁! (with i=1, …, K-1) we have 
 
P(zero DFS) = exp − log 2 𝑁!𝑁!  +   log 1 + log 2 𝑁!𝑁!!!!!                     (Eq. 2)  
 
The distribution of DFSs can be well approximated by a Poisson 
distribution. Since in a Poisson distribution, the probability of zero events is 
 
P(zero events) = exp (− λ)                                                                                        (Eq. 3)  
 
where λ is mean number of events. Then 
 λ = −log P(zero events)                                                                                         (Eq. 4)  
 
Combining Eq. 4 with Eq. 2 we can therefore calculate the mean number of 
DFSs in human cell lines. 
 
Computational experiments on RO depletion were performed by randomly 
sampling a given percentage of ROs from the data for each chromosome with 
the extreme excluded, and by computing the mean number of DFSs using Eq. 
2 and Eq. 4. Computational experiments on RO augmentation were 
performed by inserting a given percentage of new ROs in random positions on 
the each chromosome. To bolster biological reality and for compatibility with 
the RO dataset used, insertion that resulted in the creation of replicon smaller 
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than 4kb were ignored. Each computational experiment was repeated 100 
times to account for stochastic variability. The standard error of the mean 
associated with the expected number of DFSs was consistently lower than 
0.1% and therefore was not reported. 
 
ChIP Sequencing Experiments 
Two technical replicas were performed for each for each of five ChIP 
experiments on 53BP1 and IgG control. Each experiment was associated to 
unique key (Supp Figure 5A). Quality of the reads was assessed using the qa 
function of the ShortRead R package (30). The analysis is based on a sample 
of 1M reads for each replica. Diagnostic plots (Supp Figure 5B and 5C) 
indicate a consistently good quality of the reads, and no trimming was 
deemed necessary. Reads were aligned to the human genome UCSC version 
h19, to ensure compatibility with the replication origin dataset, using the align 
function of the Rsubread package with default parameter values (31). 
Alignments containing indels were ignored. The number and percentage of 
aligned reads were consistently high, as indicated by the Supp Figure 5A. 
Since cells were pre-extracted using CSK treatment, the aligned reads were 
tested for contamination from mitochondrial DNA. Contamination was 
detected in both technical replicas of 53BP1 in experiment 5, with an amount 
of mitochondrial DNA up to ~100 higher than other replicas. This was 
considered as an indication of potential problems in the experimental 
procedure, and both technical replicas were excluded from further analysis. 
All the remaining experiment and technical replicas were combined into a 
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single file containing the 53BP1 and IgG reads (MorenoEtAl_IgG.bam), sorted 
and indexed using samtools version 1.2.  
 
Analysis of binding events 
Aligned 53BP1 and IgG reads were associated with a unique replicon by 
considering the initial position of the reads. Since the total number of reads 
was significantly different for the two antibodies, the number of reads for each 
replicon was normalised by dividing it by the total number of chromosomal 
reads of the antibody under consideration. For each replicon, the ratio of the 
normalized number of reads was then considered. More formally, for each 
replicon i, 53BP1 signal Sig! was computed as 
 
Sig! =  53BP1!53BP1!! IgG!IgG!!  
 
Where 53BP1!  and IgG!  are the numbers of 53BP1 and IgG reads 
associated with replicon i, and the index j varies along all the replicons of the 
chromosome under consideration. To account for the noise associated with 
the ChIP-Seq experimental pipeline, the replicons were then grouped 
according to their size and the mean of each group was computed. In the 
most populated length group, the mean was associated with a limited errors, 
however, very large and very small replicons are characterized by a much 
larger uncertainty. Moreover, areas with limited mappability can be frequently 
observed in large replicons, resulting in a weakened 53BP1 signal (See Supp 
Figure 5D which reports the same information of Figure 3B with error bars 
indicating the standard error of the mean).  
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To assess 53BP1 enrichment, the gnome was divided in contiguous areas 
of 1 kbp and for each area k, Sig! computed as discussed above. For each 
chromosome, Sig!  is approximately log-normally distributed. It is therefore 
possible to use a fitted log-normal distribution to associate, which each area k, 
a p-value that indicate the probability of observing by chance a value of Sig! 
as large as observed or more.  
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Experiment Key Reads Aligned reads 
53BP1 Experiment 1 – Technical replica 1 1 15’085’705 13’431’878 (89.04 %) 
53BP1 Experiment 1 – Technical replica 2 2 15’085’705  13’289’715 (88.09 %) 
53BP1 Experiment 2 – Technical replica 1 3 25’316’792 22’624’95’5 (89.37 %) 
53BP1 Experiment 2 – Technical replica 2 4 25’316’792 22’427’05’5 (88.59 %) 
53BP1 Experiment 3 – Technical replica 1 5 29’105’981 25’570’708 (87.85 %) 
53BP1 Experiment 3 – Technical replica 2 6 29’105’981 25’320’996 (87.00 %) 
53BP1 Experiment 4 – Technical replica 1 7 35’869’224 31’837’763 (88.76 %) 
53BP1 Experiment 4 – Technical replica 2 8 35’869’224 31’546’518 (87.95 %) 
53BP1 Experiment 5 – Technical replica 1 9 18’644’065 16’632’221 (89.21 %) 
53BP1 Experiment 5 – Technical replica 2 10 18’644’065 16’468’113 (88.33 %) 
 IgG Experiment 1 – Technical replica 1 1 18’585’722 16’502’266 (88.79 %) 
 IgG Experiment 1 – Technical replica 2 2 18’585’722 16’368’731 (88.07 %) 
 IgG Experiment 2 – Technical replica 1 3 14’856’583 13’250’134 (89.19 %) 
 IgG Experiment 2 – Technical replica 2 4 14’856’583 13’130’364 (88.38 %) 
 IgG Experiment 3 – Technical replica 1 5 17’489’711 15’158’814 (86.67 %) 
 IgG Experiment 3 – Technical replica 2 6 17’489’711 15’002’940 (85.78%) 
 IgG Experiment 4 – Technical replica 1 7 32’639’637 28’864’826 (88.43 %) 
 IgG Experiment 4 – Technical replica 2 8 32’639’637 28’550’761 (87.47 %) 
 IgG Experiment 5 – Technical replica 1 9 37’701’283 34’159’997 (90.61 %) 
 IgG Experiment 5 – Technical replica 2 10 37’701’283 33’851’465 (89.79 %) 
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Figure S4. Details of 53BP1 ChIP-Seq
A) Experiment names, key and number of 
reads. Details of the alignment can be found 
in Supplementary Material. B-C) ChIP-Seq 
quality analysis for 53BP1 (B) and IgG (C). 
Quality score with respect to the length of the 
reads (left) and quality distribution (right). D) 
Plot of the average 53BP1/IgG signal ratio 
per kilobase against replicon size including 
S.E.M. 
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Figure S5. 53BP1 ChIP-Seq distributions.
A) Sum intensity of 53BP1 in the nucleus and in Nuclear Bodies obtained by quantifying microscopy 
images of cells expressing GFP-53BP1. B) Immunblot of 53BP1 in CSK-extracted and soluble 
fractions of HeLa cells. C) Distribution of ChIP-Seq reads for 53BP1 and control IgG across the 
entire human genome, with DNA grouped into 1 kb bins. D) ChIP-Seq 53BP1/IgG ratio for Common 
Fragile Sites. E) Mean replication timing computed for each 1kb genomic region enriched in 53BP1 
using timing data from Weddington et al (BMC Bioinformatics 9:530). The null distribution, using all 
the values reported for HeLa, is plotted for comparison (left). The distributions are significantly 
different (Wilcoxon signed rank test p-value <10^-10).. F) Frequency of 53BP1+ and 53BP1- 
replicons of different sizes (Chi-Squared p-value = 5*10-4). G) Plating efficiency of cells for 
clonogenic assays. Graph shows the mean ± SEM of three independent experiments for untreated 
cells and for the four different genotypes used in the clonogenic assays. 
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